Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Top European Drugmakers Announce Failures

By R&D Editors | December 21, 2011

PARIS (AP) – Three top European pharmaceutical companies announced disappointing news from clinical tests on drugs they had hoped would turn out to be big sellers.

France’s Sanofi said its multiple sclerosis drug candidate teriflunomide did not achieve one of its goals in a late-stage clinical trial, while Swiss rival Novartis announced it would terminate trials of its high blood pressure treatment Rasilez for patients with diabetes and renal impairment. Britain-based AstraZeneca abandoned plans to develop a new anti-ovarian cancer drug.

Sanofi said teriflunomide, also known by the trade name Aubagio, worked no better than an older drug, Rebif, in preventing relapses, as the study found “no statistical superiority” between Rebif and either 7 mg or 14 mg doses of teriflunomide. Rebif is marketed by Merck KGaA of Germany.

Sanofi’s Genzyme unit enrolled 324 patients with relapsing forms of MS in a two-year study.

The study was the second of five planned efficacy studies of teriflunomide in MS. Genzyme expects to file an application for marketing approval in the European Union in the first quarter of 2012.

In Basel, Switzerland, Novartis said it was terminating a trial of its high blood pressure treatment Rasilez in high-risk patients with diabetes and renal impairment.

The drugmaker said in a statement that it terminated the study on the recommendation of the independent monitoring committee overseeing the trial. The committee found that patients were unlikely to benefit from treatment with Rasilez, and also identified higher incidences of non-fatal stroke, renal complications and other difficulties.

Rasilez, known as Tekturna in the U.S., had sales of $449 million in the first nine months of 2011 and Novartis expects sales will be negatively affected by the study results going forward. Novartis said that as a precautionary measure it will cease promotion of Rasilez/Tekturna-based products for use in combination with standard anti-hypertension treatments.

British drugmaker AstraZeneca PLC said it is abandoning plans to develop a new anti-ovarian cancer drug and that a planed antidepressant has underperformed in tests.

The British drug company said that it would take a one-time pre-tax loss of $285 million for the failure of olaparib – a drug that was meant to fight ovarian cancer.

It added that the underperformance of the antidepressant, known as TC-5214, in tests would cost it another $96.5 million, pre-tax.

Date: December 20, 2011
Source: Associated Press

Related Articles Read More >

New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
R&D 100 winner of the day: Portable EnGineered Analytic Sensor with aUtomated Sampling (PEGASUS)
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars